Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 2/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.40 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3898059 | 1.00 | CA2 (0.47) | CA2MAPK1NOD1CTSKMME | |
| SCHEMBL6238817 | 0.89 | CA2 (0.52) | CA2MAPK1NOD1MMEACE | |
| SCHEMBL16750050 | 0.87 | CHRM1 (0.46) | CA2MAPK1NOD1MMESLC1A3 | |
| SCHEMBL5131686 | 0.87 | CHRM1 (0.46) | CA2MAPK1NOD1MMESLC1A3 | |
| SCHEMBL5131687 | 0.87 | CHRM1 (0.46) | CA2MAPK1NOD1MMESLC1A3 | |
| SCHEMBL22745777 | 0.84 | CA2 (0.48) | CA2MAPK1NOD1MMEACE | |
| SCHEMBL15160777 | 0.83 | BLM (0.44) | ACE | |
| SCHEMBL8248644 | 0.82 | PLA2G2A (0.51) | CA2MAPK1NOD1CTSKMME | |
| SCHEMBL5869797 | 0.82 | PLA2G2A (0.51) | CA2MAPK1NOD1CTSKMME | |
| SCHEMBL25460712 | 0.82 | CTSK (0.43) | CA2MAPK1NOD1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099676-A1 | SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 | SHIONOGI & CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099676-A1 | SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 | MMP13, MMP3, MMP26 | CA2 161/4885MAPK1 711/4885NOD1 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.